VEGFA and neoplasm: A lack of patient response to anti-VEGF therapies, tumor regrowth and disease progression indicate the evasion of therapeutic inhibition of angiogenesis by cancer cells due to the possible development of resistance by one or more alternative angiogenic contributing pathways.